ES2061963T3 - Briostatinas inmunomoduladoras. - Google Patents

Briostatinas inmunomoduladoras.

Info

Publication number
ES2061963T3
ES2061963T3 ES89300174T ES89300174T ES2061963T3 ES 2061963 T3 ES2061963 T3 ES 2061963T3 ES 89300174 T ES89300174 T ES 89300174T ES 89300174 T ES89300174 T ES 89300174T ES 2061963 T3 ES2061963 T3 ES 2061963T3
Authority
ES
Spain
Prior art keywords
ctl
bryostatin
ril
triggering
bryostatins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89300174T
Other languages
English (en)
Inventor
George Robert Pettit
Michail V Sitkovsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona Board of Regents of ASU
Arizona State University ASU
Original Assignee
Arizona Board of Regents of ASU
Arizona State University ASU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizona Board of Regents of ASU, Arizona State University ASU filed Critical Arizona Board of Regents of ASU
Application granted granted Critical
Publication of ES2061963T3 publication Critical patent/ES2061963T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

BAJAS CONCENTRACIONES DE LOS ACTIVADORES DE PROTEINA QUINASA C, BRIOTATINAS 1 Y 2, SIMERGIZADAS CON BSF - 1 SON UTILES PARA INICIAR DIFERENCIACION (EXPRESION DE ENCIMA DE GRANULOS) Y DESARROLLO DE CTL EN CELULAS - T NATIVAS DE NODOS LINFATICOS EN REPOSO. LA BRIOSTATINA AUMENTA MUCHO LA EFICACIA DE RIL - 2 PARA INICIAR EL DESARROLLO DE CTL PREPARADO IN VIVO DURANTE LA INCUBACION IN VITRO, PROPORCIONANDO ASI EVIDENCIA DEL USO DE CONCENTRACIONES MAS BAJAS DE RIL - 2 EN EL RECHAZO DE TUMORES IN VIVO. AMBAS BRIOSTATINAS 1 Y 2, INICIAN CITOTOXICIDAD DE CLONES CTL FRENTE A CELULAS DIANA QUE NO LLEVAN AG E INHIBEN LA CITOTOXICIDAD DE CTL FRENTE A CELULAS DIANA AG ESPECIFICAS. LAS BRIOSTATINAS 1 Y 2 SE SIMERGIZAN CON IONOFOROS DE CA2+ PARA INICIAR LA EXOCITOSIS DE GRANULOS CITOLITICOS DE CTL A CONCENTRACIONES MUY BAJAS. A CAUSA DE LA FALTA DE ACTIVIDAD PROMOTORA DE TUMORES DE LAS BRIOSTATINAS, SON UTILES COMO FARMACOS INMUNOMODULADORES Y COMO POTENCIADORES DE RIL - 2 EN INMUNOTERAPIA DE ADOPCION.
ES89300174T 1988-01-13 1989-01-10 Briostatinas inmunomoduladoras. Expired - Lifetime ES2061963T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14491288A 1988-01-13 1988-01-13

Publications (1)

Publication Number Publication Date
ES2061963T3 true ES2061963T3 (es) 1994-12-16

Family

ID=22510713

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89300174T Expired - Lifetime ES2061963T3 (es) 1988-01-13 1989-01-10 Briostatinas inmunomoduladoras.

Country Status (5)

Country Link
EP (1) EP0324574B1 (es)
JP (1) JP2973322B2 (es)
AT (1) ATE97321T1 (es)
DE (1) DE68910704T2 (es)
ES (1) ES2061963T3 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681860A (en) * 1993-09-21 1997-10-28 The Trustees Of Columbia University In The City Of New York Method of increasing expression of HLA, cell surface and TAA antigens of cells using 3-(N-acetylamino)-5-(N-decyl-N-methylamino)-benzyl alcohol
EP0969869A2 (en) * 1996-07-26 2000-01-12 Susan P. Perrine Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders
US6197743B1 (en) 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
WO1999040883A2 (en) 1998-02-11 1999-08-19 Faller Douglas V Compositions and methods for the treatment of cystic fibrosis
US7256286B2 (en) 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20050065205A1 (en) 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
CA2617003A1 (en) 2005-07-29 2007-02-08 Blanchette Rockefeller Neurosciences Institute Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory
EP2959914A1 (en) 2007-02-09 2015-12-30 Blanchette Rockefeller Neurosciences, Institute Therapeutic effects of bryologs on head trauma-induced memory impairment and brain injury
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
CN102802412A (zh) 2009-12-08 2012-11-28 海玛奎斯特医药公司 用于治疗红细胞病症的方法及低剂量方案
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
US20180030095A1 (en) 2015-02-13 2018-02-01 George Robert Pettit Silstatin compounds
WO2019094709A1 (en) 2017-11-09 2019-05-16 Pettit George R Betulastatin compounds
EP3976198A4 (en) 2019-05-31 2023-07-19 Viracta Subsidiary, Inc. METHODS OF TREATMENT OF VIRAL ASSOCIATED CANCER WITH HISTONE DEACETYLASE INHIBITORS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
EP0149551A3 (en) * 1984-01-16 1987-09-23 Genentech, Inc. Gamma interferon-interleukin-2 synergistic compositions and processes therefor
DE3704389A1 (de) * 1987-02-12 1988-08-25 Blutspendedienst Dt Rote Kreuz Verfahren zur herstellung von lymphokinen durch induktion lymphoider zellen

Also Published As

Publication number Publication date
DE68910704T2 (de) 1994-04-07
EP0324574B1 (en) 1993-11-18
JPH01308228A (ja) 1989-12-12
EP0324574A2 (en) 1989-07-19
EP0324574A3 (en) 1990-12-05
DE68910704D1 (de) 1993-12-23
JP2973322B2 (ja) 1999-11-08
ATE97321T1 (de) 1993-12-15

Similar Documents

Publication Publication Date Title
DE68910704D1 (de) Immunmodulierende Bryostatine.
Ruscetti et al. Human T-lymphocyte growth factor: regulation of growth and function of T lymphocytes
Gelfand et al. Selective toxicity of purine deoxynucleosides for human lymphocyte growth and function
Stanners The effect of cycloheximide on polyribosomes from hamster cells
ATE74510T1 (de) Adoptivimmuntherapie als behandlungsmodalitaet bei menschen.
GB2196636B (en) Production of proteins by cell culture
FI873648A (fi) Nya 9-deazaguaniner.
US6071509A (en) Enhanced activation of natural killer cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
Gale et al. The role of hematopoietic growth factors in nuclear and radiation accidents
Mastro et al. Suppression of lectin-stimulated DNA synthesis in bovine lymphocytes by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate
Hoessli et al. Potentiation of the T lymphocyte response to mitogens: IV. Serum-free production and testing of macrophage soluble products
Chuang et al. Modulation of lymphocyte proliferation by enzymes that degrade amino acids
Balish et al. Methionine biosynthesis in Escherichia coli: induction and repression of methylmethionine (or adenosylmethionine): homocysteine methyltransferase
Al-Homsi et al. Ex vivo expansion of hematopoietic stem and progenitor cells
KITAGAWA et al. Studies on drug metabolism. IV. Effects of high dose administration of pentobarbital and phenylbutazone on the plasma biologic half lives in various species
AU7336687A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
NO960710D0 (no) Nye tripeptider nyttige i immun- og CNS-terapi
Wicker et al. 5-Halo-6-phenyl pyrimidinones and 8-substituted guanosines: Biological response modifiers with similar effects on B cells
Fridenshteĭn et al. The humoral nature of the colony-stimulating action of bone marrow cells on stromal colony formation in bone marrow cultures
Dong et al. Alterations in intracellular lymphocyte metabolism induced by infection and injury
CHARAK et al. Augmentation of murine hematopoiesis by interleukin 2-activated irradiated T cells
FI873153A (fi) Menetelmä ihmisen antitrombiini III:n (ATIII:n) valmistamiseksi nisäkässoluviljelmässä sekä tähän soveltuvia vektoreita ja nisäkäsisäntäsoluja
Goodwin et al. Captopril as an antidepressant: lack of effect in animal models of serotonergic function.
GR3006212T3 (es)
ES516991A0 (es) Procedimiento para la preparacion de composiciones derivadas de cisteina o sus homologos con acido folico.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 324574

Country of ref document: ES